This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
9 Meters Biopharma Toekomstige groei
Future criteriumcontroles 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for 9 Meters Biopharma.
Belangrijke informatie
41.4%
Groei van de winst
39.9%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 18.3% |
Inkomstengroei | 56.6% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 30 May 2023 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | N/A | -43 | N/A | N/A | 2 |
12/31/2024 | N/A | -41 | N/A | N/A | 3 |
12/31/2023 | 3 | -43 | N/A | N/A | 4 |
3/31/2023 | N/A | -46 | -37 | -37 | N/A |
12/31/2022 | N/A | -44 | -37 | -37 | N/A |
9/30/2022 | N/A | -41 | -35 | -35 | N/A |
6/30/2022 | N/A | -46 | -36 | -34 | N/A |
3/31/2022 | N/A | -43 | -36 | -33 | N/A |
12/31/2021 | N/A | -37 | -32 | -29 | N/A |
9/30/2021 | N/A | -32 | -30 | -28 | N/A |
6/30/2021 | N/A | -27 | -24 | -24 | N/A |
3/31/2021 | N/A | -63 | -26 | -23 | N/A |
12/31/2020 | N/A | -61 | -23 | -19 | N/A |
9/30/2020 | N/A | -65 | -19 | -16 | N/A |
6/30/2020 | N/A | -66 | -19 | -16 | N/A |
3/31/2020 | N/A | -26 | -16 | -16 | N/A |
12/31/2019 | N/A | -27 | -18 | -18 | N/A |
9/30/2019 | N/A | -22 | -17 | -17 | N/A |
6/30/2019 | N/A | -14 | -17 | -17 | N/A |
3/31/2019 | N/A | -14 | -12 | -12 | N/A |
12/31/2018 | N/A | -24 | -15 | -15 | N/A |
9/30/2018 | N/A | -22 | -15 | -15 | N/A |
6/30/2018 | N/A | -24 | -12 | -12 | N/A |
3/31/2018 | N/A | -23 | -11 | -11 | N/A |
12/31/2017 | N/A | -12 | -5 | -5 | N/A |
9/30/2017 | N/A | -11 | -4 | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 2Q3A is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 2Q3A is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 2Q3A is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: 2Q3A's revenue (56.6% per year) is forecast to grow faster than the German market (3.3% per year).
Hoge groei-inkomsten: 2Q3A's revenue (56.6% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 2Q3A's Return on Equity is forecast to be high in 3 years time